BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 17873720)

  • 21. Neuroprotective therapies for glaucoma.
    Song W; Huang P; Zhang C
    Drug Des Devel Ther; 2015; 9():1469-79. PubMed ID: 25792807
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Don't give up on erythropoietin as a neuroprotective agent.
    Dame C; Fahnenstich H
    Pediatrics; 2005 Aug; 116(2):521-2. PubMed ID: 16061619
    [No Abstract]   [Full Text] [Related]  

  • 23. Neuroprotection: extrapolating from neurologic diseases to the eye.
    Danesh-Meyer HV; Levin LA
    Am J Ophthalmol; 2009 Aug; 148(2):186-191.e2. PubMed ID: 19464671
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Glaucoma neuroprotection--how far is it from a dream to reality].
    Ge J
    Zhonghua Yan Ke Za Zhi; 2008 May; 44(5):385-7. PubMed ID: 18953889
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Status and perspectives of neuroprotective therapies in glaucoma: the European Glaucoma Society White Paper.
    Tamm ER; Schmetterer L; Grehn F
    Cell Tissue Res; 2013 Aug; 353(2):347-54. PubMed ID: 23712457
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Retinal ganglion cells death in glaucoma--mechanism and potential treatment. Part I].
    Rokicki W; Dorecka M; Romaniuk W
    Klin Oczna; 2007; 109(7-9):349-52. PubMed ID: 18260296
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Immunological aspects in glaucoma].
    Istrate B
    Oftalmologia; 2010; 54(2):44-7. PubMed ID: 20827910
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Medicine. A boost for translational neuroscience.
    Ehrenreich H
    Science; 2004 Jul; 305(5681):184-5. PubMed ID: 15247460
    [No Abstract]   [Full Text] [Related]  

  • 29. Erythropoietin as a neuroprotective agent.
    Bell SG
    Neonatal Netw; 2011; 30(2):135-9. PubMed ID: 21402522
    [No Abstract]   [Full Text] [Related]  

  • 30. Feasibility of intravitreal erythropoietin injections in humans.
    Lagrèze WA; Feltgen N; Bach M; Jehle T
    Br J Ophthalmol; 2009 Dec; 93(12):1667-71. PubMed ID: 19692373
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Retinal ganglion cell neuroprotection in a rat model of glaucoma following brimonidine, latanoprost or combined treatments.
    Hernández M; Urcola JH; Vecino E
    Exp Eye Res; 2008 May; 86(5):798-806. PubMed ID: 18394603
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Translational Pharmacology in Glaucoma Neuroprotection.
    Levin LA
    Handb Exp Pharmacol; 2017; 242():209-230. PubMed ID: 27752844
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Polymeric delivery of neuroprotective compounds to the vitreous cavity: a potential treatment for glaucoma.
    Young MJ; Klassen HJ
    Arch Soc Esp Oftalmol; 2006 Aug; 81(8):429-32. PubMed ID: 16933165
    [No Abstract]   [Full Text] [Related]  

  • 34. Rational basis for the development of coenzyme Q10 as a neurotherapeutic agent for retinal protection.
    Russo R; Cavaliere F; Rombolà L; Gliozzi M; Cerulli A; Nucci C; Fazzi E; Bagetta G; Corasaniti MT; Morrone LA
    Prog Brain Res; 2008; 173():575-82. PubMed ID: 18929135
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Neuroprotection and regeneration in glaucoma.
    Levin LA
    Ophthalmol Clin North Am; 2005 Dec; 18(4):585-96, vii. PubMed ID: 16314221
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Rise and fall of minocycline in neuroprotection: need to promote publication of negative results.
    Diguet E; Gross CE; Tison F; Bezard E
    Exp Neurol; 2004 Sep; 189(1):1-4. PubMed ID: 15296829
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Erythropoietin as a neuroprotective agent in traumatic brain injury Review.
    Mammis A; McIntosh TK; Maniker AH
    Surg Neurol; 2009 May; 71(5):527-31; discussion 531. PubMed ID: 18789503
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Neuroprotective properties and mechanisms of erythropoietin in in vitro and in vivo experimental models for hypoxia/ischemia.
    van der Kooij MA; Groenendaal F; Kavelaars A; Heijnen CJ; van Bel F
    Brain Res Rev; 2008 Nov; 59(1):22-33. PubMed ID: 18514916
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Molecular and cell-based approaches for neuroprotection in glaucoma.
    Lebrun-Julien F; Di Polo A
    Optom Vis Sci; 2008 Jun; 85(6):417-24. PubMed ID: 18521011
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Advances in glaucoma therapeutics.
    Clark AF; Pang IH
    Expert Opin Emerg Drugs; 2002 May; 7(1):141-63. PubMed ID: 15989541
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.